Women with elevated breast cancer risk could see mortality benefit from estrogen-blocking drugs

byGeorgetown University Medical CenterCredit: Unsplash/CC0 Public DomainWhile it has long been recognized that drugs that block the cancer-promoting activity of estrogen reduce risk of developin

Updated on: December 19,2023

Women with elevated breast cancer risk could see mortality benefit from estrogen-blocking drugs

byGeorgetown University Medical CenterCredit: Unsplash/CC0 Public DomainWhile it has long been recognized that drugs that block the cancer-promoting activity of estrogen reduce risk of developin

Updated on:December 19,2023

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on: November 07,2023

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on:November 07,2023

Team learns how to predict triple negative breast cancer recurrence

byIndiana University School of MedicineCredit: Anna CarreraIndiana University School of Medicine researchers have discovered how to predict whether triple negative breast cancer will recur, and

Updated on: December 22,2023

Team learns how to predict triple negative breast cancer recurrence

byIndiana University School of MedicineCredit: Anna CarreraIndiana University School of Medicine researchers have discovered how to predict whether triple negative breast cancer will recur, and

Updated on:December 22,2023

First test of anti-cancer agent PAC-1 in human clinical trials shows promise

by Diana Yates,University of Illinois at Urbana-ChampaignProcaspase-3 (PC-3) expressions in diverse tumor histologies categorized as moderate-to-strong immunostaining intensities. Credit:B

Updated on: December 27,2023

First test of anti-cancer agent PAC-1 in human clinical trials shows promise

by Diana Yates,University of Illinois at Urbana-ChampaignProcaspase-3 (PC-3) expressions in diverse tumor histologies categorized as moderate-to-strong immunostaining intensities. Credit:B

Updated on:December 27,2023

What you need to know after a breast cancer diagnosis

by Robin FosterBreast cancer strikes 1 in 8 women in the United States, but being diagnosed with the disease can still make you feel alone.To cope with such devastating news, breast cancer surgeons fr

Updated on: October 24,2024

What you need to know after a breast cancer diagnosis

by Robin FosterBreast cancer strikes 1 in 8 women in the United States, but being diagnosed with the disease can still make you feel alone.To cope with such devastating news, breast cancer surgeons fr

Updated on:October 24,2024

Novel drug shows promising efficacy for patients with multiple myeloma

by Jenny Owen,Emory UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDResults of an international clin

Updated on: December 18,2023

Novel drug shows promising efficacy for patients with multiple myeloma

by Jenny Owen,Emory UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDResults of an international clin

Updated on:December 18,2023

Technology that determines success of CAR T-cell immunotherapy could advance treatment of lymphoma

by Laurie Fickman,University of HoustonNavin Varadarajan, M.D. Anderson Professor of chemical and biomolecular engineering, studied the dynamic interactions between T cells and tumor cells to de

Updated on: December 26,2023

Technology that determines success of CAR T-cell immunotherapy could advance treatment of lymphoma

by Laurie Fickman,University of HoustonNavin Varadarajan, M.D. Anderson Professor of chemical and biomolecular engineering, studied the dynamic interactions between T cells and tumor cells to de

Updated on:December 26,2023

Analyzing a Study on the Therapeutic Potential of Targeting IL-20RB in Lung Cancer Bone Metastasis

Updated on: September 15,2024

Analyzing a Study on the Therapeutic Potential of Targeting IL-20RB in Lung Cancer Bone Metastasis

Updated on:September 15,2024

Genetic analysis of the most common type of bladder cancer yields guidance on treatment options

byUNC Lineberger Comprehensive Cancer CenterUC-GENOME study design and molecular subtyping shows enrichment of Stroma-rich primary tumors in metastatic datasets. Credit:Nature Communicatio

Updated on: December 21,2023

Genetic analysis of the most common type of bladder cancer yields guidance on treatment options

byUNC Lineberger Comprehensive Cancer CenterUC-GENOME study design and molecular subtyping shows enrichment of Stroma-rich primary tumors in metastatic datasets. Credit:Nature Communicatio

Updated on:December 21,2023

Improving treatment for hairy cell leukemia

by Melissa Rohman,Northwestern UniversityCredit: Unsplash/CC0 Public DomainPatients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent respon

Updated on: December 22,2023

Improving treatment for hairy cell leukemia

by Melissa Rohman,Northwestern UniversityCredit: Unsplash/CC0 Public DomainPatients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent respon

Updated on:December 22,2023

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Updated on: December 21,2023

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Updated on:December 21,2023

BRAF Mutation: Cancer Types, Testing, Treatment

BRAF Mutation: Cancer Types, Testing, TreatmentRole of BRAF mutations in melanoma, lung cancer, and moreByLynne Eldridge, MDUpdated on October 14, 2022Medically reviewed byOliv

Updated on: January 28,2024

BRAF Mutation: Cancer Types, Testing, Treatment

BRAF Mutation: Cancer Types, Testing, TreatmentRole of BRAF mutations in melanoma, lung cancer, and moreByLynne Eldridge, MDUpdated on October 14, 2022Medically reviewed byOliv

Updated on:January 28,2024